What are the best treatments for Cadasil (Cerebral Autosomal Dominant Arteriopathy With Sub-Cortical Infarcts And Leukoencephalopathy)?

Currently, there is no curative treatment for Cerebral Autosomal Dominant Arteriopathy with Sub-Cortical Infarcts and Leukoencephalopathy (CADASIL); therefore, management focuses on symptom control and aggressive vascular risk factor modification. Treatment plans are highly personalized to address individual neurological needs, such as stroke prevention, migraine management, and cognitive support.

What are the primary medical strategies for managing CADASIL?

Because CADASIL is a hereditary small-vessel disease, clinicians prioritize preventing further ischemic damage. This involves the strict management of vascular risk factors. While no disease-modifying therapy is currently FDA-approved, the following strategies are standard of care:

• Antiplatelet therapy: Medications such as aspirin or clopidogrel (Plavix) are frequently prescribed to reduce the risk of ischemic stroke.


• Vascular Risk Control: Rigorous management of hypertension, hyperlipidemia (often using statins), and diabetes is essential to protect remaining blood vessel integrity.


• Migraine Management: Patients often require specific therapies for CADASIL-associated migraines, though triptans are generally avoided due to their vasoconstrictive properties.

How do non-pharmacological interventions support patients?

For those living with CADASIL, multidisciplinary rehabilitation is vital for maintaining quality of life. Physical therapy is instrumental in addressing gait disturbances and balance issues, while occupational therapy helps patients navigate cognitive changes or motor challenges in their daily routines. Speech therapy is also beneficial if the disease progression impacts communication or swallowing functions.

Are there emerging treatments or clinical trials for CADASIL?

Research into CADASIL is rapidly evolving. Current clinical trials are investigating potential neuroprotective agents and therapies aimed at the Notch3 signaling pathway, which is genetically implicated in the condition. Patients are encouraged to monitor platforms like ClinicalTrials.gov to see if they meet the criteria for emerging studies.

Which specialists should be on a CADASIL care team?

Managing CADASIL requires a coordinated, multidisciplinary approach. Your care team should ideally include a neurologist (preferably a stroke specialist), a vascular medicine expert, a neuropsychologist to track cognitive health, and a genetic counselor to discuss family implications.

Next steps

• Consult with a board-certified neurologist to create a personalized vascular risk management plan.


• Join the DiseaseMaps.org community to connect with the 57 members currently sharing their experiences with CADASIL.


• Maintain a detailed log of neurological symptoms to share with your care team during follow-up visits.

Medical disclaimer: This information is for educational purposes only and does not constitute medical advice; please consult your physician for personalized treatment decisions.

References

• NIH Genetic and Rare Diseases Information Center (GARD): CADASIL


• Orphanet: Cerebral Autosomal Dominant Arteriopathy with Sub-Cortical Infarcts and Leukoencephalopathy


• OMIM (Online Mendelian Inheritance in Man): NOTCH3 gene entry


• The CADASIL Foundation: Patient resources and clinical updates